No Data
yixintang pharmaceutical (002727.SZ): Currently, some stores of the company have obtained the qualification for outpatient unified planning.
On November 12th, yixintang pharmaceutical (002727.SZ) stated on the investor interaction platform that currently some stores of the company have obtained outpatient coordination qualifications, and the company will strictly follow the coordination requirements to carry out corresponding services in the future.
AVIC Securities: Pharmaceutical industry performance under pressure in the third quarter, total market value of heavyweight in fund holdings increased.
The demand for blood sector in biological products remains high, with vaccines facing sales pressure due to factors such as previous market consumption; active pharmaceutical ingredients are entering the tail end of downstream inventory, showing an improvement in demand, and future performance is expected to gradually improve.
yixintang pharmaceutical (002727): 3Q24 performance under pressure, reiterates "hold" rating
We predict the company's revenue and net income attributable to the mother CAGR for 2023-2026 are 2% and 3% respectively. Accelerate expansion outside Yunnan Province; create new revenue growth points. Reiterate "hold" rating; lower the DCF target price to 15.
yixintang pharmaceutical (002727.SZ): The repurchase is completed, with a total expenditure of 0.135 billion yuan to repurchase 10.4013 million shares.
On November 5th, Yixintang Pharmaceutical (002727.SZ) announced that as of November 4, 2024, the company repurchased a total of 10.4013 million shares through the special securities account for share repurchases through centralized bidding trading method, accounting for 1.7452% of the company's total share capital, with the highest fill price at 15.43 yuan/share, the lowest fill price at 10.91 yuan/share, and a total fill amount of 0.135 billion yuan (excluding transaction fees). The buyback program has been completed.
Yixintang Pharmaceutical Group Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
yixintang pharmaceutical (002727): Short-term performance under pressure, accelerating expansion of stores outside the province.
Event: The company released its third-quarter report for 2024, achieving revenue of 13.59 billion yuan (+6.1%) in the first three quarters, achieving a net income attributable to the parent of 0.29 billion (-57.4%), and achieving a non-net profit attributable to the parent of 3.4 billion.
No Data
No Data